Current status of genetic modification of T cells for cancer treatment

References

• Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–91
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333: 1038–44
   PubMed Web of Science ®Google Scholar
• Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999; 50: 369–86
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29–44
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–55
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375–7
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–22
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666–75
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623–33
   PubMed Web of Science ®Google Scholar
• Straathof, KC, Bollard, CM, Popat, U, , et al. Treatment of nasopharyngeal carcinoma with Epstein–Barr virus-specific T lymphocytes. Blood. 2005;105:1898–904.
   Google Scholar
• Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995; 270: 470–5
   PubMed Web of Science ®Google Scholar
• Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Ther 2003; 10: 902–11
   PubMed Web of Science ®Google Scholar
• Riddell SR, Elliot M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216–23
   PubMed Web of Science ®Google Scholar
• Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997; 276: 1719–24
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551–5
   PubMed Web of Science ®Google Scholar
• Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63–72
   PubMed Web of Science ®Google Scholar
• Bunnell BA, Metzger M, Byrne E, et al. Efficient in vivo marking of primary CD4+ T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector. Blood 1997; 89: 1987–95
   PubMed Web of Science ®Google Scholar
• Pollok KE, Hanenberg H, Noblitt TW, et al. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol 1998; 72: 4882–92
   Google Scholar
• Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther 2000; 1: 49–55
   PubMed Web of Science ®Google Scholar
• Humeau LM, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther 2004; 9: 902–13
   PubMed Web of Science ®Google Scholar
• Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385–9
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–76
   PubMed Web of Science ®Google Scholar
• Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371–80
   PubMed Web of Science ®Google Scholar
• Feinstein L, Sandmaier B, Maloney D, et al. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001; 938: 328–37
   PubMed Web of Science ®Google Scholar
• Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy 2003; 5: 227–30
   PubMed Web of Science ®Google Scholar
• Tiberghien P. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J Intern Med 2001; 249: 369–77
   PubMed Web of Science ®Google Scholar
• Berger C, Blau CA, Huang ML, et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004; 103: 1261–9
   PubMed Web of Science ®Google Scholar
• Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101: 1290–8
   PubMed Web of Science ®Google Scholar
• Straathof, KC, Pule, M, Yotnda, P, , et al. An inducible caspase 9 safety switch for T cell therapy. Blood, Epub 22 February 2005.
   Google Scholar
• Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000; 11: 611–20
   PubMed Web of Science ®Google Scholar
• Burt RK, Drobyski WR, Seregina T, et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 2003; 31: 903–10
   PubMed Web of Science ®Google Scholar
• Sauce D, Bodinier M, Garin M, et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein–Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002; 99: 1165–73
   PubMed Web of Science ®Google Scholar
• Bondanza A, Ciceri F, Bonini C. Application of donor lymphocytes expressing a suicide gene for early GVL Induction and later control of GVH reactions after bone-marrow transplantation. Meth Mol Med 2005; 109: 475–86
   Google Scholar
• Roskrow MA, Suzuki N, Gan Y-J, et al. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood 1998; 91: 2925–34
   PubMed Web of Science ®Google Scholar
• Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367–9
   PubMed Web of Science ®Google Scholar
• Brenner MK, Heslop HE. Is retroviral gene marking too dangerous to use?. Cytotherapy 2003; 5: 190–3
   Google Scholar
• Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99: 3179–87
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7: 1118–22
   PubMed Web of Science ®Google Scholar
• Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004; 11: 81–91
   PubMed Web of Science ®Google Scholar
• Dotti, G, Savoldo, B, Pule, M, , et al. Human cytotoxic T-lymphocytes with reduced sensitivity to fas-induced apoptosis. Blood, Epub 15 February 2005.
   Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–4
   PubMed Web of Science ®Google Scholar
• Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167: 6356–65
   PubMed Web of Science ®Google Scholar
• Yamada G, Kitamura Y, Sonoda H, et al. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 1993; 6: 2705–9
   Google Scholar
• Nelson BH, Lord JD, Greenberg PD. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T cell proliferation. Nature 1994; 369: 333–6
   PubMed Web of Science ®Google Scholar
• Foley R, Lawler M, Hollywood D. Gene-based therapy in prostate cancer. Lancet Oncol 2004; 5: 469–79
   Google Scholar
• Yotnda, P, Savoldo, B, Charlet-Berguerand, N, , et al. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood. 2004;104:2272–80.
   Google Scholar
• Pule M, Bollard CM, Heslop HE. Genetically engineered T-cells for adoptive immunotherapy. Curr Opin Mol Ther 2002; 4: 467–75
   Google Scholar
• Riviere I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. Curr Hematol Rep 2004; 3: 290–7
   Google Scholar
• Jensen M. Strategies to enhance the therapeutic efficacy of autologous hematopoietic stem cell transplantation by posttransplantation adoptive transfer of T cells with engineered graft-versus-tumor activity. Biol Blood Marrow Transplant 2005; 11: 34–9
   Google Scholar
• Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein–Barr virus-encoded peptide. Clin Immunol 2001; 98: 220–8
   PubMed Web of Science ®Google Scholar
• Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962–70
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003; 102: 3530–40
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279–86
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785–93
   PubMed Web of Science ®Google Scholar
• Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637–44
   PubMed Web of Science ®Google Scholar
• Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 2003; 5: 211–26
   PubMed Web of Science ®Google Scholar
• Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161: 2791–7
   PubMed Web of Science ®Google Scholar
• Rossig C, Bollard CM, Nuchtern JG, et al. Epstein–Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 2002; 99: 2009–16
   PubMed Web of Science ®Google Scholar
• Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004; 199: 885–94
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002; 20: 1221–27
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–6
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–19
   PubMed Web of Science ®Google Scholar
• Kohn DB, Sadelain M, Dunbar C, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8: 180–7
   PubMed Web of Science ®Google Scholar
• Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477–88
   PubMed Web of Science ®Google Scholar
• Brenner MK, Heslop HE. Is retroviral gene marking too dangerous to use?. Cytotherapy 2003; 5: 190–3
   Google Scholar
• Bonini C, Ciceri F, Apperley J, Slavin S. Hsv-Tk engineered donor lymphocytes provides early immune reconstitution and control of GvDH after haplo-identical hemopoietic stem cell transplantation [abstract]. Blood 2003; 102: 155a
   Google Scholar
• Champlin R, Bensinger W, Henslee-Downey J. Phase I/II study of tymidine kinase (TK)-transduced donor lymphocyte infusion (DLI) in patients with hematologic malignancies [abstract]. Blood 1999; 94: 324a
   Google Scholar
• Burt RK, Drobyski WR, Seregina T, et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 2003; 31: 903–10
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–8
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bonin C, Marktel S. Long term follow-up in 30 patients receiving HSV-TK transduced donor lymphocytes after allo-BMT [abstract]. Blood 1999; 94: 668a
   Google Scholar